In summary, hyperphosphatemia can be seen as the initiating factor in a series of regulatory mechanisms during the VC process secondary to CKD, mediating the expression of BMP2 and RUNX2, which are crucial molecules affecting the VC process. This evidence concerns the gene RUNX2 and chronic kidney disease.